Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Combined With Sintilimab and TACE for Inoperable HCC
NCT05971199Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05971199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05971199.